New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 17, 2014
05:40 EDTENTA, ABBVAbbVie announces EMA validation of MMAs for GT1 HCV treatment
AbbVie (ABBV) and Entana Pharmaceuticals (ENTA) announced that the Marketing Authorization Applications, or MAAs, for its investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1, or GT1, hepatitis C virus, or HCV, infection have been validated and are under accelerated assessment by the European Medicines Agency, or EMA. Accelerated assessment, which is designated to new medicines of major public health interest, was granted by the EMA for AbbVie's investigational HCV regimen in May. Validation of the MAAs confirms that the submissions are complete and starts the EMA's centralized review process. If approved, AbbVie's regimen could be available for marketing in the European Union in 1Q15. The MAAs were submitted on May 8 and are supported by data from a large clinical program including six Phase III studies of more than 2,300 GT1 patients in over 25 countries. Review of the MAAs will be conducted under the centralized licensing procedure, which, when finalized, provides marketing authorizations in all 28 member states of the EU. On June 13, AbbVie announced that the New Drug Application for AbbVie's regimen was accepted and granted priority review by the FDA.
News For ABBV;ENTA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2014
07:32 EDTENTAEnanta reports Q4 EPS (27c), consensus (33c)
Subscribe for More Information
November 21, 2014
08:10 EDTENTA, ABBVEnanta says CHMP grants positive opinions of AbbVie's Viekirax + Exviera
Subscribe for More Information
08:05 EDTABBVCHMP grants positive opinions of VIEKIRAX/EXVIERA combo for Hep C
Subscribe for More Information
07:47 EDTABBVAbbVie price target raised to $72 from $65 at Morgan Stanley
Morgan Stanley raised AbbVie's price target to $72 based on greater Humira durability of U.S. revenues. The firm believes branded Humira rebates will make it more difficult for biosimilars to gain traction. The firm rates shares an Outperform.
November 19, 2014
07:52 EDTABBVInforma Business Information to hold a conference
Subscribe for More Information
07:09 EDTABBVJefferies to hold a conference
2014 Global London Healthcare Conference is being held in London, England on November 19-20.
November 18, 2014
06:39 EDTABBVAstraZeneca: 'Hard to comment' on whether Pfizer will come back, Reuters reports
Subscribe for More Information
November 17, 2014
09:24 EDTABBVAbbVie to present data on investigational oncology compounds at ASH
AbbVie announced it will present data evaluating three investigational compounds from the company's oncology pipeline at the upcoming 56th American Society of Hematology Annual Meeting, or ASH, December 6-9. Data will be highlighted in 13 accepted abstracts, including several oral presentations detailing new trial results from the venetoclax program in acute myelogenous leukemia, elotuzumab in multiple myeloma, and duvelisib in patients with chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma. Meeting abstracts are available at the ASH website, the company said.
November 14, 2014
17:27 EDTABBVPaulson & Co. gives quarterly update on stakes
Subscribe for More Information
17:07 EDTABBVSoros Fund Management gives quarterly update on stakes
Subscribe for More Information
16:51 EDTABBVAbbVie presents ABT-414 study, will initiate randomized phase 2 trial of ABT-414
Subscribe for More Information
14:53 EDTABBVCVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
10:00 EDTABBVOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: AbbVie (ABBV) initiated with a Buy at Deutsche Bank... Advance Auto Parts (AAP) initiated with a Buy at Sterne Agee... AutoZone (AZO) initiated with an Underperform at Sterne Agee... Carter's (CRI) initiated with a Buy at Sterne Agee... Children's Place (PLCE) initiated with a Neutral at Sterne Agee... Container Store (TCS) initiated with a Fair Value at CRT Capital... DHT Holdings (DHT) initiated with a Buy at UBS... Diana Shipping (DSX) initiated with a Neutral at UBS... Genuine Parts (GPC) initiated with a Neutral at Sterne Agee... National Oilwell (NOV) initiated with a Neutral at UBS... Navios Acquisition (NNA) initiated with a Buy at UBS... NeoStem (NBS) assumed with a Buy at Maxim... O'Reilly Automotive (ORLY) initiated with a Neutral at Sterne Agee... Scorpio Bulkers (SALT) initiated with a Neutral at UBS... Star Bulk Carriers (SBLK) initiated with a Neutral at UBS... Teekay Tankers (TNK) initiated with a Buy at UBS... The Buckle (BKE) initiated with an Underweight at BB&T... TriMas (TRS) initiated with an Overweight at JPMorgan... TriplePoint Venture (TPVG) initiated with a Buy at UBS... Tsakos Energy (TNP) initiated with a Buy at UBS... USD Partners (USDP) initiated with an Outperform at Credit Suisse... Zumiez (ZUMZ) initiated with a Buy at BB&T.
07:14 EDTABBVAmerican College of Rheumatology is holding a meeting
2014 ACR/ARHP Annual Meeting is being held in Boston on November 14-19.
05:46 EDTABBVAbbVie initiated with a Buy at Deutsche Bank
Subscribe for More Information
November 11, 2014
09:06 EDTABBVAbbVie announces positive results from chronic hepatitis C patients study
Subscribe for More Information
09:04 EDTABBV, ENTAEnanta announces results from TURQUOISE-I, CORAL-I studies
Subscribe for More Information
08:13 EDTABBVAbbVie announces positive results from Phase 2b study PEARL-I
Subscribe for More Information
08:11 EDTENTA, ABBVEnanta announces rseults from Phase 2b PEARL-I study
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use